Regression of chemotherapy-resistant polymerase ϵ (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5682-5687

  Santin, Alessandro D ^a   Bellone, Stefania ^a   Buza, Natalia ^a   Choi, Jungmin ^a   Schwartz, Peter E ^a   Schlessinger, Joseph ^a   Lifton, Richard P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CEDIRANIB; CISPLATIN; DNA DIRECTED DNA POLYMERASE EPSILON; DOCETAXEL; DOXORUBICIN; MEGESTROL ACETATE; NIVOLUMAB; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN MSH6; ANTINEOPLASTIC AGENT; DNA DIRECTED DNA POLYMERASE ALPHA; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; LAPAROTOMY; MSH6 GENE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OFF LABEL DRUG USE; OMENTECTOMY; POLE GENE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME; UTERUS SURGERY; DRUG EFFECTS; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DNA POLYMERASE II; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85006163806     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1031     Document Type: Article

References (9)

1. Kandoth C, Schultz N, Cherniack A.D., Akbani R., Liu Y, Shen H, et al Integrated genomic characterization of endometrial carcinoma. Cancer Genome Atlas Res Netw Nat 2013; 497:67-73.
2. Zhao S, Choi M, Overton J.D., Bellone S., Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 2013; 110:2916-21.
3. Howitt BE, Shukla SA, Sholl L.M., Ritterhouse SA, Watkins JC, Rodig S, et al Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015; 1: 1319-23.
4. Le DT, Uram JN, Wang H, Bartlett B.R., Kemberling H., Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:26;2509-20.
5. Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I., et al. A panoply of errors: Polymerase proofreading domain mutations in cancer. Nat Rev Cancer 2016; 16:71-81.
6. Konstantinopoulos PA, Matulonis UA POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for lynch syndrome testing. Cancer 2015; 121:331-4.
7. Aghajanian C, Filiaci VL, Dizon D.S., Carlson J., Powell MA, Alvarez-Secorde A, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumabas initial therapy for measurable stage IIIorIVA, stage IVBorrecurrent endometrial cancer, GOG-86P. J Clin Oncol 33, 2015 (suppl; abstr 5500).
8. Bellone S, Centritto F, Black J., Schwab C, English D, Cocco E., et al. Polymerase e (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol 2015; 138:11-7.
9. Santin AD, Moore KN, Gunderson C, Gowen K., Fabrizio D, Frampton G.M, et al. Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). J Clin Oncol 34, 2016 (suppl; abstr 5591).